Which has better earnings and valuation, AVIR or CMPS?

Compass Pathways is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A Compass Pathways N/A N/A -$287.86M -$4.62 N/A

Is AVIR or CMPS more profitable?

Compass Pathways' return on equity of -49.63% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Compass Pathways N/A -49.63% -13.08%

Does the media refer more to AVIR or CMPS?

In the previous week, Compass Pathways had 6 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Compass Pathways and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.57 beat Compass Pathways' score of 0.04 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AVIR or ETON?

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.31 beat Atea Pharmaceuticals' score of 0.57 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, AVIR or AVLN?

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A Avalyn Pharma N/A N/A N/A -$22.81 N/A

Is AVIR or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Avalyn Pharma N/A N/A N/A

Does the media prefer AVIR or AVLN?

In the previous week, Avalyn Pharma had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for Avalyn Pharma and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.57 beat Avalyn Pharma's score of 0.30 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ANIP or AVIR?

In the previous week, ANI Pharmaceuticals had 14 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 15 mentions for ANI Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.76 beat Atea Pharmaceuticals' score of 0.57 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, AVIR or LBRX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A LB Pharmaceuticals N/A N/A -$25.20M -$3.44 N/A

Is AVIR or LBRX more profitable?

LB Pharmaceuticals' return on equity of -25.92% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% LB Pharmaceuticals N/A -25.92% -24.68%

Does the media refer more to AVIR or LBRX?

In the previous week, LB Pharmaceuticals had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for LB Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.57 beat LB Pharmaceuticals' score of 0.42 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Atea Pharmaceuticals (AVIR) Competitors

$5.33 +0.07 (+1.33%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.32 -0.01 (-0.19%)

As of 09/18/2026 07:30 PM Eastern

Compare

AVIR vs. CMPS, ETON, AVLN, ANIP, and LBRX

Should you buy Atea Pharmaceuticals stock or one of its competitors? Atea Pharmaceuticals's main competitors and comparable companies include Compass Pathways (CMPS), Eton Pharmaceuticals (ETON), Avalyn Pharma (AVLN), ANI Pharmaceuticals (ANIP), and LB Pharmaceuticals (LBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Atea Pharmaceuticals compare to Compass Pathways?

Atea Pharmaceuticals (NASDAQ:AVIR) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Atea Pharmaceuticals currently has a consensus target price of $7.00, suggesting a potential upside of 31.33%. Compass Pathways has a consensus target price of $23.36, suggesting a potential upside of 53.77%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts plainly believe Compass Pathways is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Compass Pathways is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Atea Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market.

In the previous week, Compass Pathways had 6 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Compass Pathways and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.57 beat Compass Pathways' score of 0.04 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Compass Pathways' return on equity of -49.63% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Compass Pathways	N/A	-49.63%	-13.08%

Summary

Compass Pathways beats Atea Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Eton Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.31 beat Atea Pharmaceuticals' score of 0.57 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atea Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Eton Pharmaceuticals has a net margin of 12.02% compared to Atea Pharmaceuticals' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Eton Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Eton Pharmaceuticals	$79.95M	19.84	-$4.60M	$0.38	146.05

Atea Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 31.33%. Eton Pharmaceuticals has a consensus target price of $67.50, indicating a potential upside of 21.62%. Given Atea Pharmaceuticals' higher possible upside, equities research analysts clearly believe Atea Pharmaceuticals is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Eton Pharmaceuticals beats Atea Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Avalyn Pharma?

Atea Pharmaceuticals (NASDAQ:AVIR) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, Avalyn Pharma had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for Avalyn Pharma and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.57 beat Avalyn Pharma's score of 0.30 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Atea Pharmaceuticals presently has a consensus price target of $7.00, indicating a potential upside of 31.33%. Avalyn Pharma has a consensus price target of $60.00, indicating a potential upside of 90.36%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Avalyn Pharma is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

Avalyn Pharma's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Avalyn Pharma	N/A	N/A	N/A

Summary

Avalyn Pharma beats Atea Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, ANI Pharmaceuticals had 14 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 15 mentions for ANI Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.76 beat Atea Pharmaceuticals' score of 0.57 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.98	$78.34M	$4.64	16.41
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ANI Pharmaceuticals has a net margin of 11.07% compared to Atea Pharmaceuticals' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

ANI Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

ANI Pharmaceuticals presently has a consensus target price of $103.00, indicating a potential upside of 35.28%. Atea Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 31.33%. Given ANI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

ANI Pharmaceuticals beats Atea Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to LB Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, LB Pharmaceuticals had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for LB Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.57 beat LB Pharmaceuticals' score of 0.42 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals' return on equity of -25.92% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

Atea Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential upside of 31.33%. LB Pharmaceuticals has a consensus price target of $49.63, indicating a potential upside of 16.85%. Given Atea Pharmaceuticals' higher possible upside, analysts plainly believe Atea Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Atea Pharmaceuticals and LB Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$421.88M	$12.48B	$7.26B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	-2.56	797.25	275.79	25.40
Price / Sales	N/A	950.97	695.58	114.47
Price / Cash	N/A	88.44	77.42	51.66
Price / Book	1.51	10.53	10.46	6.33
Net Income	-$158.35M	$2.82B	$3.49B	$358.33M
7 Day Performance	0.38%	1.69%	0.59%	1.12%
1 Month Performance	-4.65%	0.83%	-2.01%	-2.67%
1 Year Performance	85.07%	3.90%	18.09%	6.01%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	2.1775 of 5 stars	$5.33 +1.3%	$7.00 +31.3%	+79.5%	$421.88M	N/A	N/A	55	High Trading Volume
CMPS Compass Pathways	2.4375 of 5 stars	$14.04 +5.8%	$23.36 +66.4%	+199.0%	$1.84B	N/A	N/A	120
ETON Eton Pharmaceuticals	4.565 of 5 stars	$59.35 +1.5%	$67.50 +13.7%	+200.7%	$1.67B	$79.95M	156.18	20	Positive News
AVLN Avalyn Pharma	3.481 of 5 stars	$37.62 +0.6%	$60.00 +59.5%	N/A	$1.66B	N/A	N/A	51
ANIP ANI Pharmaceuticals	4.1784 of 5 stars	$70.23 -1.4%	$105.83 +50.7%	-21.9%	$1.64B	$883.37M	15.14	600	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. CMPS, ETON, AVLN, ANIP, and LBRX

How does Atea Pharmaceuticals compare to Compass Pathways?

Summary

How does Atea Pharmaceuticals compare to Eton Pharmaceuticals?

Summary

How does Atea Pharmaceuticals compare to Avalyn Pharma?

Summary

How does Atea Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Atea Pharmaceuticals compare to LB Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. CMPS, ETON, AVLN, ANIP, and LBRX

How does Atea Pharmaceuticals compare to Compass Pathways?

Do analysts recommend AVIR or CMPS?

Which has better earnings and valuation, AVIR or CMPS?

Which has more risk and volatility, AVIR or CMPS?

Does the media refer more to AVIR or CMPS?

Do institutionals & insiders hold more shares of AVIR or CMPS?

Is AVIR or CMPS more profitable?

Summary

How does Atea Pharmaceuticals compare to Eton Pharmaceuticals?

Do institutionals and insiders have more ownership in AVIR or ETON?

Does the media prefer AVIR or ETON?

Which has more risk and volatility, AVIR or ETON?

Is AVIR or ETON more profitable?

Which has preferable earnings & valuation, AVIR or ETON?

Do analysts rate AVIR or ETON?

Summary

How does Atea Pharmaceuticals compare to Avalyn Pharma?

Does the media prefer AVIR or AVLN?

Do institutionals & insiders believe in AVIR or AVLN?

Do analysts recommend AVIR or AVLN?

Which has stronger earnings and valuation, AVIR or AVLN?

Is AVIR or AVLN more profitable?

Summary

How does Atea Pharmaceuticals compare to ANI Pharmaceuticals?

Does the media favor ANIP or AVIR?

Which has higher earnings and valuation, ANIP or AVIR?

Do insiders & institutionals have more ownership in ANIP or AVIR?

Is ANIP or AVIR more profitable?

Which has more volatility & risk, ANIP or AVIR?

Do analysts rate ANIP or AVIR?

Summary

How does Atea Pharmaceuticals compare to LB Pharmaceuticals?

Which has higher valuation & earnings, AVIR or LBRX?

Do insiders and institutionals believe in AVIR or LBRX?

Does the media refer more to AVIR or LBRX?

Is AVIR or LBRX more profitable?

Do analysts prefer AVIR or LBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools